PYXS (Pyxis Oncology, Inc. Common Stock) Stock Analysis - SEC Filings

Pyxis Oncology, Inc. Common Stock (PYXS) is a publicly traded Healthcare sector company. As of May 21, 2026, PYXS trades at $2.00 with a market cap of $127.98M and a P/E ratio of -1.47. PYXS moved +4.71% today. Year to date, PYXS is +65.29%; over the trailing twelve months it is +65.29%. Its 52-week range spans $0.83 to $5.55. Analyst consensus is strong buy with an average price target of $6.33. Rallies surfaces PYXS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find PYXS SEC filings?

Rallies organizes PYXS SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

PYXS Key Metrics

Key financial metrics for PYXS
MetricValue
Price$2.00
Market Cap$127.98M
P/E Ratio-1.47
EPS$-1.31
Dividend Yield0.00%
52-Week High$5.55
52-Week Low$0.83
Volume0
Avg Volume0
Revenue (TTM)$13.86M
Net Income$-81.73M
Gross Margin0.00%

Latest PYXS News

Recent PYXS Insider Trades

  • HUMPHREY RACHEL sold 13.90K (~$14.36K) on Apr 21, 2025.
  • HUMPHREY RACHEL sold 200 (~$194) on Apr 17, 2025.
  • HUMPHREY RACHEL sold 1.40K (~$1.36K) on Apr 14, 2025.

PYXS Analyst Consensus

7 analysts cover PYXS: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.33.

Common questions about PYXS

Where can I find PYXS SEC filings?
Rallies organizes PYXS SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show PYXS 10-K and 10-Q filings?
Rallies organizes PYXS SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is PYXS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for PYXS. It does not provide personalized investment advice.
PYXS

PYXS